Q-omics provides the consensus-scored NDUFB7 profile across patient tissues and cancer cell-line models. NDUFB7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NDUFB7 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, NDUFB7 RNA expression shows 19,329 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, LIHC, and THYM as cancer lineages where NDUFB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB7 survival associations across molecular data types. NDUFB7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB7 RNA expression–survival associations across cancer types. High NDUFB7 expression shows unfavorable associations in KICH, SKCM, ACC and UVM, but favorable associations in CESC and MESO. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for NDUFB7 RNA expression.
This table summarizes NDUFB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB7 shows lower tumor expression in THCA and higher tumor expression in LIHC, CHOL, LUSC, COAD and ESCA. The LIHC box plot shows higher NDUFB7 RNA expression in tumor versus normal tissue (log2 FC = +0.879, t-test p < 0.001).
This table shows molecular features associated with NDUFB7 in patient tissues and cancer cell lines. In patient samples, NDUFB7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
